DE602004015142D1 - Antiangiogene peptide zur behandlung oder vorbeugung von endometriose - Google Patents

Antiangiogene peptide zur behandlung oder vorbeugung von endometriose

Info

Publication number
DE602004015142D1
DE602004015142D1 DE602004015142T DE602004015142T DE602004015142D1 DE 602004015142 D1 DE602004015142 D1 DE 602004015142D1 DE 602004015142 T DE602004015142 T DE 602004015142T DE 602004015142 T DE602004015142 T DE 602004015142T DE 602004015142 D1 DE602004015142 D1 DE 602004015142D1
Authority
DE
Germany
Prior art keywords
treating
peptides
preventing endometriosis
antiangiogenic peptides
antiangiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004015142T
Other languages
English (en)
Inventor
Judah Folkman
Kashi Javaherian
Christian Becker
Amato Robert D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Publication of DE602004015142D1 publication Critical patent/DE602004015142D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
DE602004015142T 2003-08-29 2004-08-30 Antiangiogene peptide zur behandlung oder vorbeugung von endometriose Expired - Lifetime DE602004015142D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49926403P 2003-08-29 2003-08-29
US53921304P 2004-01-26 2004-01-26
PCT/US2004/028476 WO2005042566A2 (en) 2003-08-29 2004-08-30 Antiangiogenicpeptides for treating or preventing endometriosis

Publications (1)

Publication Number Publication Date
DE602004015142D1 true DE602004015142D1 (de) 2008-08-28

Family

ID=34278655

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004015142T Expired - Lifetime DE602004015142D1 (de) 2003-08-29 2004-08-30 Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
DE602004017487T Expired - Lifetime DE602004017487D1 (de) 2003-08-29 2004-08-30 Antiangiogene peptide vom n-terminus von endostatin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004017487T Expired - Lifetime DE602004017487D1 (de) 2003-08-29 2004-08-30 Antiangiogene peptide vom n-terminus von endostatin

Country Status (10)

Country Link
US (1) US7645735B2 (de)
EP (2) EP1687426B1 (de)
JP (2) JP2007529410A (de)
KR (1) KR20070030159A (de)
AT (2) ATE412745T1 (de)
AU (2) AU2004269399A1 (de)
CA (2) CA2537179A1 (de)
DE (2) DE602004015142D1 (de)
IL (1) IL173952A0 (de)
WO (2) WO2005042566A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687426B1 (de) 2003-08-29 2008-07-16 Children's Medical Center Corporation Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN100398557C (zh) * 2006-04-05 2008-07-02 中国药科大学 血管生成抑制多肽及其制备方法和应用
CN100427503C (zh) * 2006-09-08 2008-10-22 哈尔滨医科大学 内皮抑制素小分子多肽及编码该多肽的核苷酸序列和互补链
WO2008036858A2 (en) 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
DK2244737T3 (da) 2008-01-22 2019-07-08 Univ Texas Flygtige anæstetiske sammensætninger omfattende ekstraktionsopløsningsmidler til regional anæstesi og/eller smertelindring
US8507441B2 (en) * 2009-10-22 2013-08-13 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Use of endostatin peptides for the treatment of fibrosis
IN2013MU03604A (de) 2013-11-18 2015-07-31 Indian Oil Corp Ltd
EP3071325B1 (de) 2013-11-18 2021-03-03 Indian Oil Corporation Limited Verfahren zur herstellung eines katalysators zur verbesserung der flüssigkeitsausbeute in einem thermischen verkokungsverfahren
CN113717277B (zh) * 2015-07-27 2024-02-02 上海贺普药业股份有限公司 一种肿瘤抑制肽
RU2711085C1 (ru) * 2019-08-12 2020-01-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Полипептид для ингибирования миграции и инвазии рака предстательной железы
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
CN113845582B (zh) * 2021-10-15 2022-05-27 南京市妇幼保健院 内源性多肽在制备预防或治疗子宫内膜癌靶向药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990066981A (ko) * 1995-10-23 1999-08-16 윌리엄 뉴우 치료용 맥관형성억제 조성물 및 방법
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
JP2002502814A (ja) * 1997-10-31 2002-01-29 チルドレンズ・メディカル・センター・コーポレイション 血管化した正常組織の大きさおよび増殖の調節のための方法
EP1038011B1 (de) * 1997-12-08 2006-03-08 Beth Israel Deaconess Medical Center Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia
US6653098B1 (en) * 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
AU3199999A (en) * 1998-03-24 1999-10-18 Children's Medical Center Corporation Endostatin derived peptides with anti-angiogenic and anti-cancer activity
JP2002517186A (ja) * 1998-06-03 2002-06-18 ザ チルドレンズ メディカル センター コーポレイション エンドスタチンタンパク質を含むタンパク質オリゴマー組成物およびその使用方法
PL202057B1 (pl) * 1998-08-25 2009-05-29 Merck Patent Gmbh Homodimeryczne białko fuzyjne będące inhibitorem angiogenezy, sposób jego otrzymywania oraz cząsteczka DNA i wektor ekspresyjny zawierający to DNA
US7317003B2 (en) * 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
AU4342000A (en) * 1999-04-13 2000-11-14 Merck & Co., Inc. Soluble recombinant endostatin and method of making same from (streptomyces sp)
IT1312077B1 (it) 1999-04-15 2002-04-04 Univ Degli Studi Milano Polipeptidi ad attivita' antiangiogenica.
WO2000067771A1 (en) * 1999-05-06 2000-11-16 The Burnham Institute Antiangiogenic endostatin peptides, endostatin variants and methods of use
WO2002030982A2 (en) * 2000-10-13 2002-04-18 Entremed, Inc. Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
ITMI20010394A1 (it) * 2001-02-27 2002-08-27 Univ Degli Studi Milano Peptidi ad attivita' antiangiogenica
CA2475382A1 (en) * 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
EP1687426B1 (de) 2003-08-29 2008-07-16 Children's Medical Center Corporation Antiangiogene peptide zur behandlung oder vorbeugung von endometriose

Also Published As

Publication number Publication date
EP1668129B1 (de) 2008-10-29
WO2005042566A3 (en) 2005-10-06
US20060258583A1 (en) 2006-11-16
ATE401400T1 (de) 2008-08-15
ATE412745T1 (de) 2008-11-15
KR20070030159A (ko) 2007-03-15
WO2005021756A1 (en) 2005-03-10
EP1687426B1 (de) 2008-07-16
CA2537179A1 (en) 2005-03-10
AU2004269399A1 (en) 2005-03-10
JP2007525972A (ja) 2007-09-13
IL173952A0 (en) 2006-07-05
WO2005042566A2 (en) 2005-05-12
CA2537236A1 (en) 2005-05-12
EP1668129A1 (de) 2006-06-14
DE602004017487D1 (de) 2008-12-11
US7645735B2 (en) 2010-01-12
EP1687426A2 (de) 2006-08-09
JP2007529410A (ja) 2007-10-25
AU2004285847A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
ATE530560T1 (de) Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
DE69835279D1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
DE602006016133D1 (de) Verwendung von stefin a als gerüstprotein
ATE353914T1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
ATE410441T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen
HK1080517A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
DE50004018D1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
ATE430161T1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
DE60221051D1 (de) Herstellung von peptiden und proteinen durch anhäufung in vom endoplasmatischen reticulum abgeleiteten proteinkörpern
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
MX2021011726A (es) Escindasas modificadas, usos de las mismas y kits relacionados.
DE60333728D1 (de) Tolerogene peptide des basischen myelinproteins
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
DE69837265D1 (de) Polypeptide zur regenerierung des nervensystems
DE602006017806D1 (de) Behandlung von neurodegeneration
NZ597470A (en) Therapeutic peptides, polypeptides ans nucleic acid sequences
ATE503834T1 (de) Bibliotheken rekombinanter chimärischer proteine
DE60314289D1 (de) Synthetische peptidanaloge zur behandlung von krebs
ATE369377T1 (de) Verfahren zum spalten von proteinen
CY1109617T1 (el) Ενα πεπτιδιο hsp70 που διεγειρει τη δραστηριοτητα φυσικων φονικων κυτταρων (νκ) και χρησεις αυτου
DE112005002912A5 (de) Pharmazeutisches Mittel umfassend Aminosäuren, Peptide, Proteine und/oder deren Bruchteile und Fragmente und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems bei Menschen und Tieren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition